European Nanomedicine Characterisation Laboratory
We would like to inform you that the funding, from the European Commission, supporting the H2020-EUNCL project ends on the 31st December 2019. However, the EUNCL infrastructure, along with its comprehensive analytical capabilities and harmonised SOPs, is still available. The team is aware of the needs of and continues to support, the European nanomedicine community towards the clinical translation of their products. To that end, we are developing various options to set up a fee-for-service structure, that will be fully functional from early 2020.
We wish to continue to work with you, and your organisation, to help realise your objectives. Updates concerning the new service will be posted on this website as soon as they are available. Please stay tuned.
If you are interested in the characterisation services provided by EUNCL under this new framework, please contact Research manager Dr. Geir Klinkenberg (firstname.lastname@example.org).
Our Mission is to provide a trans-disciplinary testing infrastructure covering a comprehensive set of preclinical characterisation assays (physical, chemical, in-vitro and in-vivo biological testing) allowing researchers to fully comprehend the bio distribution, metabolism, pharmacokinetics, safety profiles and immunological effects of their Med-NPs.
We are fostering the use and deployment of standard operating procedures (SOPs), benchmark materials, and quality management for the preclinical characterisation of Med-NPs (nanoparticles used for medical applications).
As nanomedicine is a fast evolving field of research, it is a key objective for EUNCL to constantly refine and adapt its assay portfolio and processes in order maintain the provision of state-of-the-art TNA to the scientific community. Therefore, we will progressively implement additional assays to increase our characterisation capacity, for instance in terms of medical application or route of administration.
The emphasis of the EUNCL is to serve as a nexus for trans-disciplinary research, development and clinical applications of nanotechnology. Therefore, lessons-learned, best practices, knowledge, tools and methods will be made available to the scientific community such as academic researchers, industry, regulatory bodies, metrology institutes and others. However, care will be taken to ensure that proprietary information and materials disclosed to the EUNCL by the TNA users are protected.
European Nanomedicine Characterisation Laboratory (EUNCL)